BIRC5 and neoplasm: LLL12B and cisplatin combination also further reduce the expression of CyclinD1 and Survivin than single agent alone (Figs. 9D, 10D), which may provide a potential mechanism of drug combination is more effective in tumor growth suppressive activity than monotherapy (Figs. 9A, 10A).